Company Filing History:
3 out of 329 
2 out of 549 
Years Active: 2019-2021
Title: The Innovative Contributions of Robert Andrew Rieger
Introduction
Robert Andrew Rieger is a notable inventor based in Boulder, CO (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target Janus kinase inhibitors. With a total of 3 patents, Rieger's work has implications for treating various diseases and disorders.
Latest Patents
Rieger's latest patents include the development of 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors. These compounds, along with their stereoisomers and pharmaceutically acceptable salts and solvates, are designed to inhibit one or more JAK kinases. They are particularly useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, and the rejection of transplanted organs, tissues, and cells. Additionally, these compounds have applications in addressing hematologic disorders and malignancies, along with their co-morbidities.
Career Highlights
Throughout his career, Rieger has worked with prominent companies in the pharmaceutical industry, including Array Biopharma Inc. and Celgene Corporation. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field.
Collaborations
Rieger has collaborated with several professionals in his field, including Shelley Allen and Mark Laurence Boys. These collaborations have further enhanced his innovative work and contributions to pharmaceutical advancements.
Conclusion
Robert Andrew Rieger's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the treatment of various diseases and disorders, showcasing the importance of innovation in healthcare.